Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016, 60400-60405 [2015-25373]
Download as PDF
60400
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
cannot guarantee that we will be able to
do so.
CALIFORNIA
Monterey County
Aeneas Sardine Packing Company Cannery,
300 Cannery Row, Monterey, 15000739
OHIO
Hamilton County
William Howard Taft National Historic Site
(Boundary Increase and Additional
Documentation, 2038 Auburn Ave.,
Cincinnati, 15000753
COLORADO
A request to move has been made for
the following resource:
Routt County
INDIANA
Hayden Co-Operative Elevator Company, 198
E. Lincoln Ave., Hayden, 15000740
Clay County
Indiana State Highway Bridge 46–11–1316,
IN 46 over Eel R., Bowling Green,
00000211
DISTRICT OF COLUMBIA
District of Columbia
Capitol Hill Historic District (Boundary
Increase II), Squares 752, 753, 777, 788
bounded by 2nd, 4th & F Sts. NE.,
Washington, 15000741
Davis, Colonel William Robert, House, 3020
Albemarle St. NW., Washington, 15000742
Young, Browne, Phelps and Springarn
Educational Campus Historic District,
(Public School Buildings of Washington,
DC MPS) 2500 Benning Rd. NE., 704, 820,
& 850 26th St. NE., Washington, 15000743
GEORGIA
In the interest of preservation a three
day comment period has been requested
for the following resource:
Toccoa Downtown Historic District
(Boundary Increase), 118 W. Doyle St.,
Toccoa, 15000744
Ozaukee County
SENATOR (steam screw) Shipwreck, (Great
Lakes Shipwreck Sites of Wisconsin MPS)
Address Restricted, Port Washington,
15000738
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–420F]
Established Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2016
BILLING CODE 4312–51–P
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
Carroll County
Manning Commercial Historic District,
(Iowa’s Main Street Commercial
Architecture MPS) 217–411, 413–507, 302–
326 Main, 717–723 3rd, 303 Center & 825
5th Sts., Manning, 15000745
JOINT BOARD FOR THE
ENROLLMENT OF ACTUARIES
Henry County
AGENCY:
Benjamin Chapel and Richwoods Cemetery,
1936 Franklin Ave., Trenton, 15000746
Boyle, Hugh and Matilda, House and
Cemetery Historic District, 3225 Lexington
Ave., Lowell, 15000747
Edwards, Joseph A. and Lydia A., House,
1735 Salem Rd., Salem, 15000748
Garretson, Owen A. and Emma J., House,
1878 335th St., Salem, 15000750
Linn County
Cedar Rapids 2nd Avenue SE. Automobile
Row Historic District, Roughly 2nd to 3rd
Aves., SE., from 6th to 8th Sts., SE., Cedar
Rapids, 15000749
Monroe Elementary School Historic District,
3200 Pioneer Ave., SE., Cedar Rapids,
15000751
tkelley on DSK3SPTVN1PROD with NOTICES
[FR Doc. 2015–25342 Filed 10–5–15; 8:45 am]
Authority: 60.13 of 36 CFR part 60
[FR Doc. 2015–25375 Filed 10–5–15; 8:45 am]
IOWA
Montgomery County
Ellis, William and Amanda J., Farmstead
Historic District, 1134 I Ave., Elliott,
15000752
NEW YORK
Essex County
Helen Hill Historic District, Prescott Place,
Helen & Front Sts., Sheppard, Franklin &
Clinton Aves., Saranac Lake, 15000754
VerDate Sep<11>2014
Dated: September 21, 2015.
Patrick W. McDonough,
Executive Director, Joint Board for the
Enrollment of Actuaries.
BILLING CODE 4830–01–P
WISCONSIN
Dated: September 16, 2015.
Roger Reed,
Acting Chief, National Register of Historic
Places/National Historic Landmarks Program.
Stephens County
mathematics, pension law and
methodology referred to in 29 U.S.C.
1242(a)(1)(B).
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the subject of the meeting falls
within the exception to the open
meeting requirement set forth in Title 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such meeting be
closed to public participation.
18:31 Oct 05, 2015
Jkt 238001
Meeting of the Advisory Committee;
Meeting
Joint Board for the Enrollment
of Actuaries
ACTION: Notice of Federal Advisory
Committee meeting.
The Executive Director of the
Joint Board for the Enrollment of
Actuaries gives notice of a closed
teleconference meeting of the Advisory
Committee on Actuarial Examinations.
DATES: The meeting will be held on
October 30, 2015, from 8:30 a.m. to 5:00
p.m.
FOR FURTHER INFORMATION CONTACT:
Patrick W. McDonough, Executive
Director of the Joint Board for the
Enrollment of Actuaries, 703–414–2173.
SUPPLEMENTARY INFORMATION:
Notice is hereby given that the
Advisory Committee on Actuarial
Examinations will hold a teleconference
meeting on October 30, 2015, from 8:30
a.m. to 5:00 p.m. The meeting will be
closed to the public.
The purpose of the meeting is to
discuss topics and questions that may
be recommended for inclusion on future
Joint Board examinations in actuarial
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
This final order establishes
the initial 2016 aggregate production
quotas for controlled substances in
schedules I and II of the Controlled
Substances Act (CSA) and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
DATES:
Effective October 6, 2015.
John
R. Scherbenske, Office of Diversion
Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (202)
598–6812.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
Legal Authority
The Drug Enforcement
Administration (DEA) implements and
enforces titles II and III of the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, as amended.
Titles II and III are referred to as the
‘‘Controlled Substances Act’’ and the
‘‘Controlled Substances Import and
Export Act,’’ respectively, and are
collectively referred to as the
‘‘Controlled Substances Act’’ or the
‘‘CSA’’ for the purpose of this action. 21
E:\FR\FM\06OCN1.SGM
06OCN1
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
U.S.C. 801–971. The DEA publishes the
implementing regulations for these
statutes in title 21 of the Code of Federal
Regulations (CFR), chapter II. The CSA
and its implementing regulations are
designed to prevent, detect, and
eliminate the diversion of controlled
substances and listed chemicals into the
illicit market while ensuring an
adequate supply is available for the
legitimate medical, scientific, research,
and industrial needs of the United
States. Controlled substances have the
potential for abuse and dependence and
are controlled to protect the public
health and safety.
Section 306 of the Controlled
Substances Act (CSA), 21 U.S.C. 826,
requires the Attorney General to
determine the total quantity and
establish production quotas for each
basic class of controlled substance in
schedules I and II and for ephedrine,
pseudoephedrine, and
phenylpropanolamine to be
manufactured each calendar year to
provide for the estimated medical,
scientific, research, and industrial needs
of the United States, for lawful export
requirements, and for the establishment
and maintenance of reserve stocks. This
responsibility has been delegated to the
Administrator of the DEA through 28
CFR 0.100(b).
Background
The 2016 aggregate production quotas
and assessment of annual needs
represent those quantities of schedule I
and II controlled substances and the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine that may be
manufactured in the United States in
2016 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine,
and phenylpropanolamine but do not
include imports of controlled
substances for use in industrial
processes.
On July 17, 2015, a notice titled,
‘‘Proposed Aggregate Production Quotas
for Schedule I and II Controlled
Substances and Proposed Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2016’’ was
published in the Federal Register. 80 FR
42540. This notice proposed the 2016
aggregate production quotas for each
basic class of controlled substance listed
in schedules I and II and the 2016
assessment of annual needs for the list
I chemicals ephedrine,
VerDate Sep<11>2014
18:31 Oct 05, 2015
Jkt 238001
pseudoephedrine, and
phenylpropanolamine. All interested
persons were invited to comment on or
object to the proposed aggregate
production quotas and the proposed
assessment of annual needs on or before
August 17, 2015.
Comments Received
Twenty comments were received from
four DEA-registered manufacturers
within the published comment period
regarding 17 different schedule I and II
controlled substances. The DEA did not
receive any comments regarding the
proposed assessment of annual needs
for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. Commenters
stated that the proposed aggregate
production quotas for [1-(5fluoropentyl)-1H-indazol-3yl](naphthalen-1-yl)methanone (THJ–
2201), amphetamine (for sale), codeine
(for sale), gamma hydroxybutric acid,
levorphanol, marihuana,
methylphenidate, N-(1-Amino-3,3dimethyl-1-oxobutan-2-yl)-1-pentyl-1Hindazole-3-carboxamide (ADB–
PINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (AB–
FUBINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-(cyclohexylmethyl)1H-indazole-3-carboxamide (AB–
CHMINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-pentyl-1H-indazole-3carboxamide (AB–PINACA), N-(1phenethylpiperidin-4-yl)-Nphenylacetamide (acetyl fentanyl),
nabilone, oxymorphone (for
conversion), oxymorphone (for sale),
Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB–22),
and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB–22) were insufficient to
provide for the estimated medical,
scientific, research, and industrial needs
of the United States, export
requirements, and the establishment
and maintenance of reserve stocks.
Determination of 2016 Aggregate
Production Quotas and Assessment of
Annual Needs
In determining the 2016 aggregate
production quotas and assessment of
annual needs, the DEA has taken into
consideration the above comments
along with the factors set forth at 21
CFR 1303.11 and 21 CFR 1315.11, in
accordance with 21 U.S.C. 826(a), and
other relevant factors, including the
2015 manufacturing quotas, current
2015 sales and inventories, anticipated
2016 export requirements, industrial
use, additional applications for 2016
quotas, as well as information on
research and product development
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
60401
requirements. Based on this
information, the DEA has determined
that adjustments to the proposed
aggregate production quotas for codeine
(for sale), hydromorphone, marihuana,
methylphenidate, and N-(1phenethylpiperidin-4-yl)-Nphenylacetamide (acetyl fentanyl) are
warranted. This final order reflects
those adjustments.
Regarding [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1yl)methanone (THJ–2201), amphetamine
(for sale), gamma hydroxybutric acid,
levorphanol, N-(1-Amino-3,3-dimethyl1-oxobutan-2-yl)-1-pentyl-1H-indazole3-carboxamide (ADB–PINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB–FUBINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3carboxamide (AB–CHMINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1pentyl-1H-indazole-3-carboxamide (AB–
PINACA), nabilone, oxymorphone (for
conversion), oxymorphone (for sale),
Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB–22),
and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB–22), the DEA has
determined that the proposed aggregate
production quotas are sufficient to
provide for the 2016 estimated medical,
scientific, research, and industrial needs
of the United States, export
requirements, and the establishment
and maintenance of reserve stocks. This
final order establishes these aggregate
production quotas at the same amounts
as proposed.
As described in the previously
published notice proposing the 2016
aggregate production quotas and
assessment of annual needs, the DEA
has specifically considered that
inventory allowances granted to
individual manufacturers may not
always result in the availability of
sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be concerning if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
available to provide for legitimate
public need. As such, the DEA has
included in all established schedule II
aggregate production quotas, and certain
schedule I aggregate production quotas,
an additional 25% of the estimated
medical, scientific, and research needs
as part of the amount necessary to
ensure the establishment and
maintenance of reserve stocks. The
established aggregate production quotas
will reflect these included amounts.
This action will not affect the ability of
E:\FR\FM\06OCN1.SGM
06OCN1
60402
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
manufacturers to maintain inventory
allowances as specified by regulation.
The DEA expects that maintaining this
reserve in certain established aggregate
production quotas will mitigate adverse
public effects if an unforeseen event
results in the substantial disruption to
the amount of controlled substances
available to provide for legitimate
public need, as determined by the DEA.
The DEA does not anticipate utilizing
the reserve in the absence of these
circumstances.
In accordance with 21 U.S.C. 826, 21
CFR 1303.11, and 21 CFR 1315.11, the
Administrator hereby establishes the
2016 aggregate production quotas for the
following schedule I and II controlled
substances and the 2016 assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Established 2016
quotas (g)
Basic class
tkelley on DSK3SPTVN1PROD with NOTICES
Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) .............................................................................
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ–2201) ...............................................................................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ...............................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) .................................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) .............................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ..................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ......................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .....................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .............................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) ........................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH–073) .....................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) ...................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ....................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .....................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ...............................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) .....................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) .................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) .....................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ....................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) .............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ....................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) .................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ...................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ...............................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36) ................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ..................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82) ...............
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) .......................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5) ..........................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ...................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...............................................................................................................................
2,5-Dimethoxyamphetamine ..........................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) .........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ..................................................................................................
3,4,5-Trimethoxyamphetamine ......................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ...........................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ....................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .....................................................................................................................................
3-Fluoro-N-methylcathinone (3–FMC) ...........................................................................................................................................
3-Methylfentanyl .............................................................................................................................................................................
3-Methylthiofentanyl .......................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ...........................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) ...........................................................................................................................................
4-Methoxyamphetamine ................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................
4-Methylaminorex ..........................................................................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) .............................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ..................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) .........................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ...................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog) ....................
5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ...............................................................................................................................................
Acetyl-alpha-methylfentanyl ...........................................................................................................................................................
VerDate Sep<11>2014
18:31 Oct 05, 2015
Jkt 238001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
E:\FR\FM\06OCN1.SGM
06OCN1
25
15
25
25
25
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
25
30
25
30
15
25
25
25
25
30
30
25
55
50
40
50
35
25
2
2
25
25
25
150
25
25
25
45
25
68
53
25
25
25
2
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
Established 2016
quotas (g)
tkelley on DSK3SPTVN1PROD with NOTICES
Basic class
Acetyldihydrocodeine .....................................................................................................................................................................
Acetylmethadol ..............................................................................................................................................................................
Allylprodine ....................................................................................................................................................................................
Alphacetylmethadol ........................................................................................................................................................................
alpha-Ethyltryptamine ....................................................................................................................................................................
Alphameprodine .............................................................................................................................................................................
Alphamethadol ...............................................................................................................................................................................
alpha-Methylfentanyl ......................................................................................................................................................................
alpha-Methylthiofentanyl ................................................................................................................................................................
alpha-Methyltryptamine (AMT) ......................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ........................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ......................................................................................................................................
Aminorex ........................................................................................................................................................................................
Benzylmorphine .............................................................................................................................................................................
Betacetylmethadol .........................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ......................................................................................................................................................
beta-Hydroxyfentanyl .....................................................................................................................................................................
Betameprodine ...............................................................................................................................................................................
Betamethadol .................................................................................................................................................................................
Betaprodine ....................................................................................................................................................................................
Bufotenine ......................................................................................................................................................................................
Cathinone .......................................................................................................................................................................................
Codeine methylbromide .................................................................................................................................................................
Codeine-N-oxide ............................................................................................................................................................................
Desomorphine ................................................................................................................................................................................
Diethyltryptamine ...........................................................................................................................................................................
Difenoxin ........................................................................................................................................................................................
Dihydromorphine ............................................................................................................................................................................
Dimethyltryptamine ........................................................................................................................................................................
Dipipanone .....................................................................................................................................................................................
Fenethylline ....................................................................................................................................................................................
gamma-Hydroxybutyric acid ..........................................................................................................................................................
Heroin ............................................................................................................................................................................................
Hydromorphinol ..............................................................................................................................................................................
Hydroxypethidine ...........................................................................................................................................................................
Ibogaine .........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ..................................................................................................................................................
Marihuana ......................................................................................................................................................................................
Mescaline .......................................................................................................................................................................................
Methaqualone ................................................................................................................................................................................
Methcathinone ...............................................................................................................................................................................
Methyldesorphine ...........................................................................................................................................................................
Methyldihydromorphine ..................................................................................................................................................................
Morphine methylbromide ...............................................................................................................................................................
Morphine methylsulfonate ..............................................................................................................................................................
Morphine-N-oxide ..........................................................................................................................................................................
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ..................................................................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB–PINACA) ...............................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB–FUBINACA) ...................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB–CHMINACA) .............................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA) .......................................................
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl) ..............................................................................................
N,N-Dimethylamphetamine ............................................................................................................................................................
Naphthylpyrovalerone (naphyrone) ...............................................................................................................................................
N-Benzylpiperazine ........................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ..................................................................................................................................................
N-Ethylamphetamine .....................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................
Noracymethadol .............................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................................
Normethadone ...............................................................................................................................................................................
Normorphine ..................................................................................................................................................................................
Para-fluorofentanyl .........................................................................................................................................................................
Parahexyl .......................................................................................................................................................................................
Phenomorphan ..............................................................................................................................................................................
Pholcodine .....................................................................................................................................................................................
Psilocybin .......................................................................................................................................................................................
Psilocyn ..........................................................................................................................................................................................
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ..................................................................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB–22; QUPIC) .................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................................
Thiofentanyl ...................................................................................................................................................................................
Tilidine ............................................................................................................................................................................................
VerDate Sep<11>2014
18:31 Oct 05, 2015
Jkt 238001
PO 00000
Frm 00055
Fmt 4703
60403
Sfmt 4703
E:\FR\FM\06OCN1.SGM
06OCN1
2
2
2
2
25
2
2
2
2
25
25
25
25
2
2
2
2
2
4
2
3
70
5
305
25
25
11,000
3,000,000
35
5
5
70,250,000
50
2
2
5
40
658,000
25
10
25
5
2
5
5
350
25
50
50
15
15
100
25
25
25
5
24
24
2
52
2
40
5
5
2
5
30
50
50
50
511,250
2
25
60404
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
Established 2016
quotas (g)
Basic class
Trimeperidine .................................................................................................................................................................................
2
Schedule II
1-Phenylcyclohexylamine ..............................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ..............................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ...................................................................................................................................
Alfentanil ........................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Amphetamine (for conversion) ......................................................................................................................................................
Amphetamine (for sale) .................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine (for conversion) ...............................................................................................................................................................
Codeine (for sale) ..........................................................................................................................................................................
Dextropropoxyphene ......................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................................
Dihydroetorphine ............................................................................................................................................................................
Diphenoxylate (for conversion) ......................................................................................................................................................
Diphenoxylate (for sale) .................................................................................................................................................................
Ecgonine ........................................................................................................................................................................................
Ethylmorphine ................................................................................................................................................................................
Etorphine hydrochloride .................................................................................................................................................................
Fentanyl .........................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Hydrocodone (for conversion) .......................................................................................................................................................
Hydrocodone (for sale) ..................................................................................................................................................................
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Meperidine Intermediate-A ............................................................................................................................................................
Meperidine Intermediate-B ............................................................................................................................................................
Meperidine Intermediate-C ............................................................................................................................................................
Metazocine .....................................................................................................................................................................................
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine .........................................................................................................................................................................
5
5
2,950,000
17,750
3
25,125
15,000,000
39,705,000
19
200,000
50,000,000
63,900,000
45
226,375
3
31,250
1,337,500
125,000
3
3
2,300,000
3
235,000
88,500,000
8,250,000
5
4
30
7,125
29,750,000
5,450,000
6
11
6
19
31,875,000
34,375,000
2,061,375
tkelley on DSK3SPTVN1PROD with NOTICES
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]
Methylphenidate .............................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Opium (powder) .............................................................................................................................................................................
Opium (tincture) .............................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxymorphone (for conversion) ......................................................................................................................................................
Oxymorphone (for sale) .................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phenazocine ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Phenylacetone ...............................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Racemorphan ................................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Tapentadol .....................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
VerDate Sep<11>2014
18:31 Oct 05, 2015
Jkt 238001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\06OCN1.SGM
06OCN1
96,750,000
91,250,000
62,500,000
18,750
17,500,000
1,475,000
112,500
687,500
30,000,000
6,250,000
139,150,000
29,000,000
7,750,000
38,125,000
6
50
3
50
3
3
3,750
215,003
6,255
25,500,000
125,000,000
60405
Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
Established 2016
quotas (g)
Basic class
List I Chemicals
Ephedrine (for conversion) ............................................................................................................................................................
Ephedrine (for sale) .......................................................................................................................................................................
Phenylpropanolamine (for conversion) ..........................................................................................................................................
Phenylpropanolamine (for sale) .....................................................................................................................................................
Pseudoephedrine (for conversion) ................................................................................................................................................
Pseudoephedrine (for sale) ...........................................................................................................................................................
The Administrator also establishes
aggregate production quotas for all other
schedule I and II controlled substances
included in 21 CFR 1308.11 and
1308.12 at zero. In accordance with 21
CFR 1303.13 and 21 CFR 1315.13, upon
consideration of the relevant factors, the
Administrator may adjust the 2016
aggregate production quotas and
assessment of annual needs as needed.
Dated: September 30, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–25373 Filed 10–5–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting and Hearing Notice No.
09–15]
tkelley on DSK3SPTVN1PROD with NOTICES
Sunshine Act Meeting
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR 503.25) and the Government in
the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of open meetings as follows:
Thursday, October 15, 2015: 10 a.m.—
Issuance of Proposed Decisions in
claims against Libya.
Status: Open
All meetings are held at the Foreign
Claims Settlement Commission, 600 E
Street NW., Washington, DC. Requests
for information, or advance notices of
intention to observe an open meeting,
may be directed to: Patricia M. Hall,
Foreign Claims Settlement Commission,
600 E Street NW., Suite 6002,
Washington, DC 20579. Telephone:
(202) 616–6975.
Brian M. Simkin,
Chief Counsel.
BILLING CODE 4410–BA–P
18:31 Oct 05, 2015
To submit
comments:
Notice of Lodging of Proposed
Consent Decree Under the Clean Air
Act
On September 29, 2015, the
Department of Justice lodged a proposed
consent decree with the United States
District Court for the Eastern District of
Michigan in the lawsuit entitled United
States v. Guardian Industries Corp.,
Civil Action No. 2:15-cv-13426.
The United States filed this lawsuit
under the Clean Air Act. The complaint
seeks injunctive relief and civil
penalties for violations of the Clean Air
Act’s Prevention of Significant
Deterioration requirements at eight float
glass manufacturing furnaces owned
and operated by the defendant,
Guardian Industries Corp., in Kingsburg,
California; DeWitt, Iowa; Carleton,
Michigan; Geneva, New York; Floreffe,
Pennsylvania; Richburg, South Carolina;
and Corsicana, Texas. The consent
decree requires the defendant to
perform injunctive relief, which
includes complying with emission
limitations that are comprised of
numerical or work practice standards
that together apply continuously at all
times. The defendant will also pay a
$312,000 civil penalty and perform a
$150,000 wood burning appliance
replacement mitigation project in the
San Joaquin Valley area in California.
The publication of this notice opens
a period for public comment on the
proposed consent decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States v. Guardian
Industries Corp., D.J. Ref. No. 90–5–2–
1–11128. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
Jkt 238001
To submit
comments:
Send them to:
By email .......
[FR Doc. 2015–25500 Filed 10–2–15; 4:15 pm]
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
pubcomment-ees.enrd@
usdoj.gov.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
100,000
4,000,000
22,400,000
8,500,000
7,000
224,500,000
Send them to:
By mail .........
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington,
D.C. 20044–7611.
During the public comment period,
the proposed consent decree may be
examined and downloaded at this
Justice Department Web site: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
proposed consent decree upon written
request and payment of reproduction
costs. Please mail your request and
payment to:
Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $24.25 (25 cents per page
reproduction cost) payable to the United
States Treasury. For a paper copy
without the exhibits and signature
pages, the cost is $19.50.
Maureen M. Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2015–25339 Filed 10–5–15; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
179th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of Meeting
Pursuant to the authority contained in
Section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 179th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans (also
known as the ERISA Advisory Council)
will be held on November 3–4, 2015.
The meeting will take place in C5320
Room 6, U.S. Department of Labor, 200
Constitution Avenue NW., Washington,
DC 20210 on November 3, from 1 p.m.
to approximately 5:00 p.m. On
E:\FR\FM\06OCN1.SGM
06OCN1
Agencies
[Federal Register Volume 80, Number 193 (Tuesday, October 6, 2015)]
[Notices]
[Pages 60400-60405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-25373]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-420F]
Established Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: This final order establishes the initial 2016 aggregate
production quotas for controlled substances in schedules I and II of
the Controlled Substances Act (CSA) and the assessment of annual needs
for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: Effective October 6, 2015.
FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of
Diversion Control, Drug Enforcement Administration, 8701 Morrissette
Drive, Springfield, VA 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces
titles II and III of the Comprehensive Drug Abuse Prevention and
Control Act of 1970, as amended. Titles II and III are referred to as
the ``Controlled Substances Act'' and the ``Controlled Substances
Import and Export Act,'' respectively, and are collectively referred to
as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of
this action. 21
[[Page 60401]]
U.S.C. 801-971. The DEA publishes the implementing regulations for
these statutes in title 21 of the Code of Federal Regulations (CFR),
chapter II. The CSA and its implementing regulations are designed to
prevent, detect, and eliminate the diversion of controlled substances
and listed chemicals into the illicit market while ensuring an adequate
supply is available for the legitimate medical, scientific, research,
and industrial needs of the United States. Controlled substances have
the potential for abuse and dependence and are controlled to protect
the public health and safety.
Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826,
requires the Attorney General to determine the total quantity and
establish production quotas for each basic class of controlled
substance in schedules I and II and for ephedrine, pseudoephedrine, and
phenylpropanolamine to be manufactured each calendar year to provide
for the estimated medical, scientific, research, and industrial needs
of the United States, for lawful export requirements, and for the
establishment and maintenance of reserve stocks. This responsibility
has been delegated to the Administrator of the DEA through 28 CFR
0.100(b).
Background
The 2016 aggregate production quotas and assessment of annual needs
represent those quantities of schedule I and II controlled substances
and the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine that may be manufactured in the United States in
2016 to provide for the estimated medical, scientific, research, and
industrial needs of the United States, lawful export requirements, and
the establishment and maintenance of reserve stocks. These quotas
include imports of ephedrine, pseudoephedrine, and phenylpropanolamine
but do not include imports of controlled substances for use in
industrial processes.
On July 17, 2015, a notice titled, ``Proposed Aggregate Production
Quotas for Schedule I and II Controlled Substances and Proposed
Assessment of Annual Needs for the List I Chemicals Ephedrine,
Pseudoephedrine, and Phenylpropanolamine for 2016'' was published in
the Federal Register. 80 FR 42540. This notice proposed the 2016
aggregate production quotas for each basic class of controlled
substance listed in schedules I and II and the 2016 assessment of
annual needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. All interested persons were invited to comment on
or object to the proposed aggregate production quotas and the proposed
assessment of annual needs on or before August 17, 2015.
Comments Received
Twenty comments were received from four DEA-registered
manufacturers within the published comment period regarding 17
different schedule I and II controlled substances. The DEA did not
receive any comments regarding the proposed assessment of annual needs
for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. Commenters stated that the proposed aggregate
production quotas for [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-
1-yl)methanone (THJ-2201), amphetamine (for sale), codeine (for sale),
gamma hydroxybutric acid, levorphanol, marihuana, methylphenidate, N-
(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide (ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), N-(1-Amino-3-
methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
(AB-CHMINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide (AB-PINACA), N-(1-phenethylpiperidin-4-yl)-N-
phenylacetamide (acetyl fentanyl), nabilone, oxymorphone (for
conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-
1H-indole-3-carboxylate (PB-22) were insufficient to provide for the
estimated medical, scientific, research, and industrial needs of the
United States, export requirements, and the establishment and
maintenance of reserve stocks.
Determination of 2016 Aggregate Production Quotas and Assessment of
Annual Needs
In determining the 2016 aggregate production quotas and assessment
of annual needs, the DEA has taken into consideration the above
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR
1315.11, in accordance with 21 U.S.C. 826(a), and other relevant
factors, including the 2015 manufacturing quotas, current 2015 sales
and inventories, anticipated 2016 export requirements, industrial use,
additional applications for 2016 quotas, as well as information on
research and product development requirements. Based on this
information, the DEA has determined that adjustments to the proposed
aggregate production quotas for codeine (for sale), hydromorphone,
marihuana, methylphenidate, and N-(1-phenethylpiperidin-4-yl)-N-
phenylacetamide (acetyl fentanyl) are warranted. This final order
reflects those adjustments.
Regarding [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
yl)methanone (THJ-2201), amphetamine (for sale), gamma hydroxybutric
acid, levorphanol, N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
1H-indazole-3-carboxamide (ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-
2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), N-(1-
Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide (AB-CHMINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
pentyl-1H-indazole-3-carboxamide (AB-PINACA), nabilone, oxymorphone
(for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-
fluoropentyl)-1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-
yl 1-pentyl-1H-indole-3-carboxylate (PB-22), the DEA has determined
that the proposed aggregate production quotas are sufficient to provide
for the 2016 estimated medical, scientific, research, and industrial
needs of the United States, export requirements, and the establishment
and maintenance of reserve stocks. This final order establishes these
aggregate production quotas at the same amounts as proposed.
As described in the previously published notice proposing the 2016
aggregate production quotas and assessment of annual needs, the DEA has
specifically considered that inventory allowances granted to individual
manufacturers may not always result in the availability of sufficient
quantities to maintain an adequate reserve stock pursuant to 21 U.S.C.
826(a), as intended. See 21 CFR 1303.24. This would be concerning if a
natural disaster or other unforeseen event resulted in substantial
disruption to the amount of controlled substances available to provide
for legitimate public need. As such, the DEA has included in all
established schedule II aggregate production quotas, and certain
schedule I aggregate production quotas, an additional 25% of the
estimated medical, scientific, and research needs as part of the amount
necessary to ensure the establishment and maintenance of reserve
stocks. The established aggregate production quotas will reflect these
included amounts. This action will not affect the ability of
[[Page 60402]]
manufacturers to maintain inventory allowances as specified by
regulation. The DEA expects that maintaining this reserve in certain
established aggregate production quotas will mitigate adverse public
effects if an unforeseen event results in the substantial disruption to
the amount of controlled substances available to provide for legitimate
public need, as determined by the DEA. The DEA does not anticipate
utilizing the reserve in the absence of these circumstances.
In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR
1315.11, the Administrator hereby establishes the 2016 aggregate
production quotas for the following schedule I and II controlled
substances and the 2016 assessment of annual needs for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Established 2016
Basic class quotas (g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1- 15
yl)methanone (THJ-2201).............................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 25
tetramethylcyclopropyl)methanone (XLR11)............
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 25
(butylone)..........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 25
(pentylone).........................................
1-(1-Phenylcyclohexyl)pyrrolidine.................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)... 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................ 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45
200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).............. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR- 45
18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).............. 45
1-Methyl-4-phenyl-4-propionoxypiperidine............. 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)... 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)... 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).. 45
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)..... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).... 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).. 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............. 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
25B; Cimbi-36)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
25C; Cimbi-82)......................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)...... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
25I; Cimbi-5).......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone).... 25
2,5-Dimethoxy-4-ethylamphetamine (DOET).............. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine........... 25
2,5-Dimethoxyamphetamine............................. 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)............................................
3,4,5-Trimethoxyamphetamine.......................... 25
3,4-Methylenedioxyamphetamine (MDA).................. 55
3,4-Methylenedioxymethamphetamine (MDMA)............. 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)......... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)..... 50
3,4-Methylenedioxypyrovalerone (MDPV)................ 35
3-Fluoro-N-methylcathinone (3-FMC)................... 25
3-Methylfentanyl..................................... 2
3-Methylthiofentanyl................................. 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)............... 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........... 25
4-Fluoro-N-methylcathinone (4-FMC)................... 25
4-Methoxyamphetamine................................. 150
4-Methyl-2,5-dimethoxyamphetamine (DOM).............. 25
4-Methylaminorex..................................... 25
4-Methyl-N-ethylcathinone (4-MEC).................... 25
4-Methyl-N-methylcathinone (mephedrone).............. 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP).. 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68
hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine.............. 25
5-Methoxy-N,N-diisopropyltryptamine.................. 25
5-Methoxy-N,N-dimethyltryptamine..................... 25
Acetyl-alpha-methylfentanyl.......................... 2
[[Page 60403]]
Acetyldihydrocodeine................................. 2
Acetylmethadol....................................... 2
Allylprodine......................................... 2
Alphacetylmethadol................................... 2
alpha-Ethyltryptamine................................ 25
Alphameprodine....................................... 2
Alphamethadol........................................ 2
alpha-Methylfentanyl................................. 2
alpha-Methylthiofentanyl............................. 2
alpha-Methyltryptamine (AMT)......................... 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).......... 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)......... 25
Aminorex............................................. 25
Benzylmorphine....................................... 2
Betacetylmethadol.................................... 2
beta-Hydroxy-3-methylfentanyl........................ 2
beta-Hydroxyfentanyl................................. 2
Betameprodine........................................ 2
Betamethadol......................................... 4
Betaprodine.......................................... 2
Bufotenine........................................... 3
Cathinone............................................ 70
Codeine methylbromide................................ 5
Codeine-N-oxide...................................... 305
Desomorphine......................................... 25
Diethyltryptamine.................................... 25
Difenoxin............................................ 11,000
Dihydromorphine...................................... 3,000,000
Dimethyltryptamine................................... 35
Dipipanone........................................... 5
Fenethylline......................................... 5
gamma-Hydroxybutyric acid............................ 70,250,000
Heroin............................................... 50
Hydromorphinol....................................... 2
Hydroxypethidine..................................... 2
Ibogaine............................................. 5
Lysergic acid diethylamide (LSD)..................... 40
Marihuana............................................ 658,000
Mescaline............................................ 25
Methaqualone......................................... 10
Methcathinone........................................ 25
Methyldesorphine..................................... 5
Methyldihydromorphine................................ 2
Morphine methylbromide............................... 5
Morphine methylsulfonate............................. 5
Morphine-N-oxide..................................... 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide 25
(AKB48).............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 50
indazole-3-carboxamide (ADB-PINACA).................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4- 50
fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1- 15
(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-
CHMINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 15
indazole-3-carboxamide (AB-PINACA)..................
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide 100
(acetyl fentanyl)...................................
N,N-Dimethylamphetamine.............................. 25
Naphthylpyrovalerone (naphyrone)..................... 25
N-Benzylpiperazine................................... 25
N-Ethyl-1-phenylcyclohexylamine...................... 5
N-Ethylamphetamine................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine.............. 24
Noracymethadol....................................... 2
Norlevorphanol....................................... 52
Normethadone......................................... 2
Normorphine.......................................... 40
Para-fluorofentanyl.................................. 5
Parahexyl............................................ 5
Phenomorphan......................................... 2
Pholcodine........................................... 5
Psilocybin........................................... 30
Psilocyn............................................. 50
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 50
carboxylate (5-fluoro-PB-22; 5F-PB-22)..............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 50
22; QUPIC)..........................................
Tetrahydrocannabinols................................ 511,250
Thiofentanyl......................................... 2
Tilidine............................................. 25
[[Page 60404]]
Trimeperidine........................................ 2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 5
1-Piperidinocyclohexanecarbonitrile.................. 5
4-Anilino-N-phenethyl-4-piperidine (ANPP)............ 2,950,000
Alfentanil........................................... 17,750
Alphaprodine......................................... 3
Amobarbital.......................................... 25,125
Amphetamine (for conversion)......................... 15,000,000
Amphetamine (for sale)............................... 39,705,000
Carfentanil.......................................... 19
Cocaine.............................................. 200,000
Codeine (for conversion)............................. 50,000,000
Codeine (for sale)................................... 63,900,000
Dextropropoxyphene................................... 45
Dihydrocodeine....................................... 226,375
Dihydroetorphine..................................... 3
Diphenoxylate (for conversion)....................... 31,250
Diphenoxylate (for sale)............................. 1,337,500
Ecgonine............................................. 125,000
Ethylmorphine........................................ 3
Etorphine hydrochloride.............................. 3
Fentanyl............................................. 2,300,000
Glutethimide......................................... 3
Hydrocodone (for conversion)......................... 235,000
Hydrocodone (for sale)............................... 88,500,000
Hydromorphone........................................ 8,250,000
Isomethadone......................................... 5
Levo-alphacetylmethadol (LAAM)....................... 4
Levomethorphan....................................... 30
Levorphanol.......................................... 7,125
Lisdexamfetamine..................................... 29,750,000
Meperidine........................................... 5,450,000
Meperidine Intermediate-A............................ 6
Meperidine Intermediate-B............................ 11
Meperidine Intermediate-C............................ 6
Metazocine........................................... 19
Methadone (for sale)................................. 31,875,000
Methadone Intermediate............................... 34,375,000
Methamphetamine...................................... 2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate...................................... 96,750,000
Morphine (for conversion)............................ 91,250,000
Morphine (for sale).................................. 62,500,000
Nabilone............................................. 18,750
Noroxymorphone (for conversion)...................... 17,500,000
Noroxymorphone (for sale)............................ 1,475,000
Opium (powder)....................................... 112,500
Opium (tincture)..................................... 687,500
Oripavine............................................ 30,000,000
Oxycodone (for conversion)........................... 6,250,000
Oxycodone (for sale)................................. 139,150,000
Oxymorphone (for conversion)......................... 29,000,000
Oxymorphone (for sale)............................... 7,750,000
Pentobarbital........................................ 38,125,000
Phenazocine.......................................... 6
Phencyclidine........................................ 50
Phenmetrazine........................................ 3
Phenylacetone........................................ 50
Racemethorphan....................................... 3
Racemorphan.......................................... 3
Remifentanil......................................... 3,750
Secobarbital......................................... 215,003
Sufentanil........................................... 6,255
Tapentadol........................................... 25,500,000
Thebaine............................................. 125,000,000
------------------------------------------------------------------------
[[Page 60405]]
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)........................... 100,000
Ephedrine (for sale)................................. 4,000,000
Phenylpropanolamine (for conversion)................. 22,400,000
Phenylpropanolamine (for sale)....................... 8,500,000
Pseudoephedrine (for conversion)..................... 7,000
Pseudoephedrine (for sale)........................... 224,500,000
------------------------------------------------------------------------
The Administrator also establishes aggregate production quotas for
all other schedule I and II controlled substances included in 21 CFR
1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21
CFR 1315.13, upon consideration of the relevant factors, the
Administrator may adjust the 2016 aggregate production quotas and
assessment of annual needs as needed.
Dated: September 30, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-25373 Filed 10-5-15; 8:45 am]
BILLING CODE 4410-09-P